Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Corgentech, AlgoRx merge

October 3, 2005 | A version of this story appeared in Volume 83, Issue 40

Corgentech and AlgoRx Pharmaceuticals have agreed to merge in a stock deal that will leave AlgoRx stockholders with a 62% stake in the combined company. The new company will focus on pain management and inflammation therapies. AlgoRx's pipeline holds three pain therapies, including candidates in Phase II and III clinical trials. Corgentech has one candidate, NF-kappaB decoy for eczema, in Phase I/II trials. Earlier this year, Corgentech's edifoligide, a drug to prevent vein graft failure after surgery, failed in trials.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.